Taylor Frigon Capital Management LLC Decreases Position in Glaukos Co. (NYSE:GKOS)

Taylor Frigon Capital Management LLC lowered its stake in Glaukos Co. (NYSE:GKOS) by 10.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,012 shares of the medical instruments supplier’s stock after selling 3,010 shares during the quarter. Glaukos comprises 1.9% of Taylor Frigon Capital Management LLC’s portfolio, making the stock its 9th biggest holding. Taylor Frigon Capital Management LLC’s holdings in Glaukos were worth $3,750,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc bought a new position in shares of Glaukos in the fourth quarter worth about $43,000. Asset Planning Inc bought a new stake in Glaukos during the 4th quarter valued at approximately $90,000. Harvest Fund Management Co. Ltd raised its stake in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares during the period. KBC Group NV raised its stake in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the period. Finally, EWA LLC bought a new stake in Glaukos during the 3rd quarter valued at approximately $209,000. Institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. The trade was a 4.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is currently owned by company insiders.

Glaukos Price Performance

Shares of Glaukos stock opened at $120.35 on Thursday. The stock has a market cap of $6.64 billion, a price-to-earnings ratio of -41.93 and a beta of 1.04. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a 50 day moving average price of $151.35 and a 200-day moving average price of $139.46. Glaukos Co. has a one year low of $83.90 and a one year high of $163.71.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on GKOS shares. UBS Group started coverage on Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 target price on the stock. Stephens raised Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. BTIG Research lifted their target price on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Stifel Nicolaus raised their price target on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Finally, Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and raised their price target for the company from $140.00 to $200.00 in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.